Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company

CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs

Fineline Cube Nov 15, 2022

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of...

Company Medical Device

Hotgen Receives NMPA Approval for HBV RNA Assay Kit

Fineline Cube Nov 15, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced that it has received marketing approval...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity

Fineline Cube Nov 15, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has announced the first patient dosing in the randomized,...

Company Drug

Guangdong Zhongsheng Starts Phase III Trial for COVID-19 Drug RAY1216

Fineline Cube Nov 15, 2022

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the enrollment of the first...

Company Drug

Yabao Receives FDA Clearance for Generic Nexavar

Fineline Cube Nov 15, 2022

China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received Abbreviated...

Company Deals

Hansoh Pharmaceutical Licenses Biotheus’ Bispecific Antibody PM1080 for Greater China

Fineline Cube Nov 15, 2022

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a licensing agreement with fellow...

Company Deals

Sansure Biotech Partners with UBC to Manufacture in Indonesia

Fineline Cube Nov 15, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has entered into a local manufacturing...

Company

HutchMed Shifts Focus to Late-Stage Pipeline for Regulatory Approvals

Fineline Cube Nov 15, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced a strategic shift to focus...

Company Deals

Harbour BioMed and WuXi Biologics Announce Strategic Collaboration

Fineline Cube Nov 15, 2022

Harbour BioMed (HKG: 2142), a global biotechnology company with operations in the United States, the...

Company Drug

Hengrui’s Pyrotinib Granted Priority Review for HER2-Positive Breast Cancer

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) website has announced that China-based Hengrui Pharmaceuticals’ (SHA: 600276)...

Policy / Regulatory

CDE Issues Guidelines for Bispecific Antibody Antitumor Drug Development

Fineline Cube Nov 15, 2022

The Center for Drug Evaluation (CDE) has released the “Technical Guidelines for Clinical Research and...

Company Drug

AstraZeneca to Launch Soliris in Hangzhou After Regulatory Approval

Fineline Cube Nov 14, 2022

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has revealed plans to sell Soliris (eculizumab)...

Company Drug

Akeso Biopharma’s AK112 Receives Two New Breakthrough Therapy Designations

Fineline Cube Nov 14, 2022

The Center for Drug Evaluation (CDE) website indicates that China-based Akeso Biopharma (HKG: 9926) has...

Company

CStone Launches Patient Assistance Program for IDH1 Inhibitor Tibsovo

Fineline Cube Nov 14, 2022

CStone Pharmaceuticals (HKG: 2616) has announced the launch of a patient assistance scheme to support...

Company Drug

HutchMed Announces Initial Results from FRUTIGA Phase III Study

Fineline Cube Nov 14, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) has announced the initial results from...

Company Deals

BRL Medicine Raises RMB 200M in Series B Financing for CGT Development

Fineline Cube Nov 14, 2022

BRL Medicine Inc., a cell and gene therapy (CGT) developer based in Shanghai, has reportedly...

Company Medical Device

Peijia Medical Enrolls First Patient in HighLife TSMVR Study

Fineline Cube Nov 14, 2022

China’s Peijia Medical Limited (HKG: 9996) has announced the enrollment of the first patient and...

Company Medical Device

Acotec Scientific Secures FDA 510(k) Approval for Vericor Catheter

Fineline Cube Nov 14, 2022

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received a 510(k)...

Company

CStone Pharmaceuticals Suspends Operations at Suzhou Plant to Cut Costs

Fineline Cube Nov 14, 2022

CStone Pharmaceuticals (HKG: 2616) has decided to suspend manufacturing operations at its Suzhou industrialization plant,...

Company Deals

Daxiang Biotech Raises RMB 100M in Pre-Series B Financing for Organoid-on-a-Chip

Fineline Cube Nov 14, 2022

Beijing-based Daxiang Biotech Co., Ltd., a leading domestic company in the organoid-on-a-chip field, has reportedly...

Posts pagination

1 … 652 653 654 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.